亚太地区生物制药合同制造市场预测至 2028 年 - COVID-19 影响和按产品（生物制品和生物仿制药）、服务（工艺开发、灌装和完成操作、分析和质量控制研究以及包装）和来源（哺乳动物和微生物）进行的区域分析-基于生物制剂/非哺乳动物）
No. of Pages: 145 | Report Code: TIPRE00010854 | Category: Life Sciences
No. of Pages: 145 | Report Code: TIPRE00010854 | Category: Life Sciences
亚洲国家正在成为有吸引力的外包地点用于生物制药行业。中国和印度较低的制造和运营成本是推动该地区生物制药合同制造市场增长的关键因素。这些国家生物制药行业最近的增长表明了该市场的积极前景。此外，不断增长的国内市场及其管道正在为亚太地区的生物制药合同制造商开辟新的途径。近年来，中国的管道呈现快速增长。据国际制药工程学会统计，2016年，国家食品药品监督管理总局（CFDA）注册了约200个新生物药品进入临床试验。此外，许多 CMO 正在扩大其制造能力，以满足不断增长的需求，从而推动生物制药合同制造市场的增长。例如，2020 年 1 月，合全药业有限公司（药明康德旗下子公司）在中国开设了一家新的大型寡核苷酸活性药物成分 (API) 生产工厂。此外，Bushu Pharmaceuticals 将与安进的合同制造协议扩大到整个亚洲，其中包括中国、台湾和韩国等国家。 CMO 预计将安进产品数量增加一倍，并将负责 Repatha、Evenity、Prolia 和 Xgeva 等药物的组装、标签、包装和检查。同样，2021 年，阿斯利康与日本 JCR 制药公司签订了生产其 COVID-19 疫苗解决方案的合同。此外，JCR还宣布决定建设新工厂。这些发展标志着制药和制药业面临着重大的新兴机遇。亚太地区生物制药公司。
Strategic insights for Asia Pacific Biopharmaceutical Contract Manufacturing involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 2,973.92 Million |
| Market Size by 2028 | US$ 5,462.23 Million |
| Global CAGR (2021 - 2028) | 9.1% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 产品
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Biopharmaceutical Contract Manufacturing refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is valued at US$ 2,973.92 Million in 2021, it is projected to reach US$ 5,462.23 Million by 2028.
As per our report Asia Pacific Biopharmaceutical Contract Manufacturing Market, the market size is valued at US$ 2,973.92 Million in 2021, projecting it to reach US$ 5,462.23 Million by 2028. This translates to a CAGR of approximately 9.1% during the forecast period.
The Asia Pacific Biopharmaceutical Contract Manufacturing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Biopharmaceutical Contract Manufacturing Market report:
The Asia Pacific Biopharmaceutical Contract Manufacturing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Biopharmaceutical Contract Manufacturing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Biopharmaceutical Contract Manufacturing Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Biopharmaceutical Contract Manufacturing Market
